Compared to Estimates, Immunocore (IMCR) Q1 Earnings: A Look at Key Metrics

For the quarter ended March 2025, Immunocore Holdings PLC Sponsored ADR (IMCR) reported revenue of $93.88 million, up 33.2% over the same period last year. EPS came in at $0.10, compared to -$0.49 in the year-ago quarter.The reported revenue represents a surprise of +7.84% over the Zacks Consensus Estimate of $87.06 million. With the consensus EPS estimate being -$0.35, the EPS surprise was +128.57%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.Here is how Immunocore performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Geographic Revenue- United States: $56.61 million versus the two-analyst average estimate of $65.33 million. Geographic Revenue- International: $4.47 million versus the two-analyst average estimate of $2.67 million. Geographic Revenue- Europe: $32.80 million compared to the $18.53 million average estimate based on two analysts. Product revenue, net: $93.88 million versus $85.61 million estimated by four analysts on average. View all Key Company Metrics for Immunocore here>>>Shares of Immunocore have returned +14.4% over the past month versus the Zacks S&P 500 composite's +10.6% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.5 Stocks Set to DoubleEach was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2024. While not all picks can be winners, previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.Today, See These 5 Potential Home Runs >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Immunocore Holdings PLC Sponsored ADR (IMCR): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks